The "hidden" Journey of Excipients: From Early Development to Commercial Manufacturing

When people think about pharmaceutical innovation, the spotlight usually falls on the API the active pharmaceutical ingredient. Yet behind every successful drug product stands an equally important, often underestimated group of materials: Excipients. Excipients are far more than inactive ingredients. They shape manufacturability, stability, bioavailability, patient experience, and ultimately the commercial success of a medicine. What makes excipient selection especially fascinating is that it evolves continuously throughout the drug development lifecycle.

In early development, formulation scientists operate with considerable flexibility. The focus is scientific exploration: understanding the API, identifying compatibility risks, improving solubility, and finding the first workable formulation prototypes. At this stage, excipient selection is driven by feasibility and speed. Multiple grades, suppliers, and technologies may be evaluated simultaneously as teams search for the optimal formulation strategy.

As programs move into preclinical and Phase I clinical development, priorities begin to shift. Formulations must now support toxicology studies and first-in-human trials. Simplicity becomes valuable. Development teams often favor well-known, compendial excipients with established regulatory acceptance and strong safety profiles. The goal is no longer only to make the formulation work in the lab it must now work reliably in humans and under accelerated development timelines.

By Phase II, excipient selection becomes far more strategic. Formulations are optimized for performance, manufacturability, and scalability. Scientists investigate excipient functionality more deeply, exploring how materials influence dissolution, tabletability, stability, patient acceptability, and process robustness. This is often the stage where formulation science and process engineering truly converge.

Phase III marks a critical transition: the formulation approaches its final commercial form. At this point, changing excipients becomes increasingly difficult, costly, and risky. Regulatory expectations rise significantly. Excipient suppliers are qualified, material attributes become tightly controlled, and long-term supply chain reliability becomes essential. The discussion is no longer only about functionality, it is equally about consistency, risk management, documentation, and global compliance.

Once the product enters commercial manufacturing, excipient management evolves again. Lifecycle management takes center stage. Companies must ensure uninterrupted supply, consistent quality, and efficient manufacturing performance over potentially decades of production. Supplier changes, sustainability initiatives, cost optimization, and regulatory updates all become part of the excipient strategy.

This progression illustrates an important reality in pharmaceutical development: excipient selection is never static. It evolves from scientific experimentation to clinical optimization, then into regulatory control and ultimately commercial reliability.

Excipient selection is never static. It evolves from scientific experimentation to clinical optimization, then into regulatory control and ultimately commercial reliability.
Philippe Tschopp, Founder Pharma Excipients

The later a project progresses, the more critical and more difficult excipient changes become. That is why excipient selection should never be viewed simply as a purchasing decision or formulation detail. It is a strategic component of pharmaceutical development that directly influences speed to clinic, manufacturability, regulatory success, and product lifecycle performance.

Below is a simplified overview of how excipient priorities evolve across the development journey.

Evolution of excipient focus throughout development

Evolution of excipient eocus throughout development — Evolution of excipient focus throughout development

How Excipient Priorities Shift Over Time

The “Locking” of Excipient Selection

In many ways, excipients quietly define the success of modern pharmaceutical development. While APIs may provide therapeutic activity, excipients enable medicines to become stable, manufacturable, scalable, and patient-friendly products.

And that makes excipients not inactive ingredients but active enablers of pharmaceutical innovation.